rAAV Purification via Anion Exchange and Zonal Ultracentrifugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying recombinant adeno-associated virus (rAAV) particles for gene therapy are hindered by the presence of impurities, including therapeutically ineffective particles with different net charges and densities, which limit the effectiveness of purification techniques.
Innovation Solution
The method employs a combination of anion exchange chromatography (AEX) and zonal ultracentrifugation (ZUC) to remove impurities with different net charges and densities, respectively, thereby isolating therapeutically effective rAAV particles by first using AEX to remove impurities with a net charge different from the rAAV particles and then using ZUC to remove those with different densities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If a single purification method is used, then the process is simple, but the purity of rAAV particles cannot reach 99%+
Solution Approach 1:
The purification process is divided into multiple sequential steps: anion exchange chromatography (AEX) as the first step to remove charged impurities, followed by zonal ultracentrifugation (ZUC) as the second step to remove density-based impurities. Each step targets specific impurity types, achieving cumulative purification效果 that reaches 99%+ purity.
Solution Approach 2:
The method selectively extracts and removes specific impurity types at each purification step. AEX extracts impurities with different net charges, while ZUC extracts impurities with different densities. This selective extraction approach efficiently concentrates therapeutically effective rAAV particles while removing various impurity types.
2Quantity of substance
If AEX is used first to remove charged impurities, then the concentration of effective particles increases, but the process time increases
Solution Approach 1:
AEX is performed as a preliminary step before ZUC to pre-concentrate therapeutically effective particles by removing charged impurities. This preliminary action increases the concentration of effective particles entering the ZUC step, making the subsequent ultracentrifugation more efficient and reducing overall processing time.
Solution Approach 2:
The two purification steps are performed in continuous sequence without interruption. The eluate from AEX flows directly into the ZUC preparation, maintaining continuous useful action throughout the purification process. This continuous approach minimizes downtime and maximizes processing efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the concentration of therapeutically effective rAAV particles, allowing for efficient processing and achieving high purity, with AEX removing up to 99% of impurities and ZUC further refining the composition to achieve heavy and partial capsids of 99%+ purity.
Implementation Method 1
removing the first portion from the composition by anion-exchange chromatography (AEX)
Implementation Method 2
removing the second portion from the composition by zonal ultracentrifugation (ZUC)
Data Source
AI summary
The present invention provides process for enriching adeno-associated virus particles using anion exchange chromatography and zonal ultracentrifugation.